Uzbekistan Foreign Adverse Event Reporting: CIOMS Format within 15 Days
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Registration No. 3752 establishes a continuous global scanning obligation: where a company identifies, outside Uzbekistan, an adverse event related to a product registered in Uzbekistan, it must report the event to the competent authority within 15 days from the date of identification, using an international standardized format, the CIOMS form. This is not a one-time requirement. It requires the company to scan global safety databases on an ongoing basis and to identify signals that affect products registered in Uzbekistan, regardless of where in the world the event occurred and regardless of whether the event would be reportable in the market where it happened. For manufacturers with a global footprint, the obligation effectively turns the Uzbekistan registration certificate into a standing reason to keep the global signal distribution list accurate and complete, and the 15-day deadline applies to the report itself, so the transfer between the manufacturer and the local representative must fit inside the same window.
2. Legal basis
| Regulation | Reference number | Date | Provisions |
|---|---|---|---|
| Order of the Minister of Health approving the Regulation on the Procedure for Pharmacovigilance of Medicines and Safety Monitoring of Medical Devices | Order No. 18; Ministry of Justice registration No. 3752 | Ministerial order December 30, 2025; Ministry of Justice registration January 12, 2026 | Adverse events identified abroad that are related to products registered in Uzbekistan must be reported to the competent authority within 15 days from the date of identification, in an international standardized format (CIOMS form) |
| Order No. 18 of the Ministry of Health (Ministry of Justice registration No. 3752) | No. 3752 | Registered on January 12, 2026 | Obligated subjects are manufacturers and registration certificate holders; on the device side, monitoring covers adverse events and incidents |
| Order No. 18 of the Ministry of Health (Ministry of Justice registration No. 3752) | No. 3752 | Registered on January 12, 2026 | Adverse events identified abroad must be reflected in the periodic safety update report (PSUR) |
| National standard on Good Pharmacovigilance Practices (GVP) | O’z MSt 339:2024 | Effective November 1, 2024 | National framework for periodic safety update reports |
3. Expert insights
Insight 1: The 15-day clock starts on the day of identification, not on the day of confirmation. The wording of registration No. 3752 is within 15 days from the date of identification. This starting point is earlier than a confirmation-based trigger: it means the company must start the clock as soon as preliminary information is available, rather than waiting until causality has been assessed and confirmed. For companies with mature global vigilance systems, this requires adding Uzbekistan to the global signal distribution list, so that relevant foreign events reach the Uzbekistan reporting workflow the moment they are identified, not after the next review meeting. In practice this means the Uzbekistan flag must be set at the case level in the database, so that the 15-day clock can be started by the system rather than by an email chain.
Insight 2: The CIOMS form is an internationally standard format, which lowers the cost of format adaptation. Because the requirement refers to an international standardized format, the CIOMS form, companies can reuse the forms already operating inside their global vigilance systems instead of developing a dedicated Uzbekistan format. For companies with existing experience in the European Union or in ICH markets, this is a material convenience: the same structured data fields, the same narrative conventions, and the same internal quality controls can be carried over without redesign. It also simplifies internal quality review, because the same completeness checks can be applied to the Uzbekistan report as to any other CIOMS submission in the global workflow.
Insight 3: Foreign events and the PSUR are linked, not parallel tracks. Registration No. 3752 additionally requires that adverse events identified abroad be reflected in the periodic safety update report (PSUR), and the PSUR is prepared according to the national GVP standard. The handling path for a foreign event is therefore: identification, reporting within 15 days using the CIOMS form, and inclusion in the PSUR. The two documents must be able to point to each other, so that the authority can trace every foreign event from the individual report through to the periodic summary without finding unexplained gaps. A practical way to maintain the link is to reference the CIOMS submission identifier in the PSUR line item for the same event, so the trace runs in both directions.
Insight 4: The global scanning obligation requires technical support and cannot be completed manually. To continuously identify foreign events related to products registered in Uzbekistan, the global safety database needs filtering conditions set by product, model, and registration number, with periodic exports and comparisons. Relying on manual reminders or on the memory of individual staff members produces systematic under-reporting, and under-reporting is precisely the failure mode most visible to a regulator during an inspection of the vigilance system. A scheduled export, for example monthly, with a documented comparison step, converts the obligation into a routine that survives staff turnover.
4. Practical recommendations
- Configure filtering conditions in the global safety database for products registered in Uzbekistan, covering product, model, and registration number; the filters should be reviewed whenever a new model or registration number is added to the portfolio.
- Use the day of identification as the timing start point and build a mechanism that starts the clock at identification, without waiting for causality confirmation.
- Reuse the CIOMS forms of the global vigilance system rather than developing a separate local format.
- Maintain a register of foreign events that cross-references the PSUR, so that the two documents never diverge.
- Agree with the local representative on the transfer format and deadlines for foreign events, ensuring that reporting can be completed within 15 days.
5. Verification checklist
- □ Filtering conditions for products registered in Uzbekistan have been configured in the global safety database
- □ The timing start point is the day of identification, not the day of confirmation
- □ CIOMS forms have been adopted, with no separate local format developed
- □ A register of foreign events has been established and cross-references the PSUR
- □ The transfer format and deadlines with the representative have been agreed, with reporting completed within 15 days
- □ A mechanism for periodic export and comparison is in place, without reliance on manual reminders
Regulatory information verified as of October 29, 2026.
GRZAN provides regulatory support to manufacturers, importers, and authorized representatives seeking medical device registration and post-market compliance in Uzbekistan, including dossier preparation, authorized representative arrangements, vigilance setup, and surveillance readiness. For inquiries, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us